CSF1R Inhibitor
Showing 1 - 25 of >10,000
Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)
Active, not recruiting
- Unresectable Intrahepatic Cholangiocarcinoma
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Jan 10, 2023
Pancreatic Cancer Trial in Baltimore (Cyclophosphamide, GVAX, Pembrolizumab)
Active, not recruiting
- Pancreatic Cancer
- Cyclophosphamide
- +3 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Jan 5, 2023
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer Trial (Q702, Pembrolizumab)
Not yet recruiting
- Esophageal Cancer
- +3 more
- Q702
- Pembrolizumab
- (no location specified)
Jun 27, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Edicotinib, Pharmacokinetic Study)
Terminated
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Edicotinib
- Pharmacokinetic Study
-
Portland, OregonOHSU Knight Cancer Institute
Dec 1, 2021
Positron Emission Tomography, Alzheimer, Neurodegenerative Diseases Trial in Shanghai ([18F]CSF-23)
Recruiting
- Positron Emission Tomography
- +2 more
- [18F]CSF-23
-
Shanghai, ChinaHuashan Hospital
Nov 19, 2023
Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) Trial in Italy (NMS-03592088)
Recruiting
- Acute Myeloid Leukemia (AML)
- Chronic Myelomonocytic Leukemia (CMML)
-
Bergamo, BG, Italy
- +4 more
Mar 23, 2021
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Thymalfasin
- +3 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023
Objective Response Rate Trial in Wuhan (GM-CSF)
Recruiting
- Objective Response Rate
-
Wuhan, Hubei, ChinaRenmin Hospital of Wuhan University
Feb 25, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Radiotherapy
- +4 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023
NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Vinorelbine
- +4 more
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 29, 2022
Assess CSF1R-related Leukoencephalopathy After Stem Cell
Enrolling by invitation
- CSF1R-related Leukoencephalopathy
- +3 more
-
Jacksonville, FloridaMayo Clinic in Florida
Dec 7, 2021
Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Dalpiciclib Isetionate Tablets, Camrelizumab
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)
Recruiting
- Neuroblastoma
- Naxitamab monotherapy
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 31, 2023
PD-1 Inhibitor, G-CSF Trial in Guangzhou (Camrelizumab, G-CSF)
Recruiting
- PD-1 Inhibitor
- G-CSF
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),
Not yet recruiting
- Nasopharyngeal Carcinoma
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022
PraG With RANKL Inhibitor for Treatment of Advanced Multiple
Not yet recruiting
- Metastatic Solid Tumor
-
Suzhou, Jiangsu, ChinaThe Second Affiliated Hospital of Soochow University
Aug 16, 2022
Advanced Refractory Solid Tumors Trial in China (Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF)
Recruiting
- Advanced Refractory Solid Tumors
- Hypofractionated radiotherapy
- +3 more
-
Beijing, China
- +15 more
Aug 8, 2022
Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1
Recruiting
- Classical Hodgkin Lymphoma
- Refractory or Relapsed Classical Hodgkin Lymphoma
- PD-1 inhibitor
- PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
-
Guangzhou, Guangdong, China
- +2 more
May 6, 2022
Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)
Recruiting
- Immunotherapy
- +3 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 2, 2021
Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor Trial in Guangzhou (PEG-rhG-CSF)
Recruiting
- Granulocyte Colony-Stimulating Factor
- PD-1 Inhibitor
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022